Printed From BioPortfolio.com
Roche boosts oncology portfolio with $1.7bn acquisition
03:59 EST 22 Dec 2017 | Pharmafile
Roche has announced that it will buy Ignyta, a San Diego-based biotech that has a pipeline of oncology drugs, for $1.7 billion.
Ignyta was formed by the University of California in 2011, with its lead candidate currently undergoing Phase 2 trials. Entrectinib is a small molecule tyrosine kinase inhibitor of NTRK family of receptors and ROS1 proteins, and the treatment is being examined to determine whether it can be effective as a treatment for solid tumours.
Original Article: Roche boosts oncology portfolio with $1.7bn acquisition
